{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Clear+Cell+Renal+Cell+Carcinoma&page=4",
    "query": {
      "condition": "Non-Clear Cell Renal Cell Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 264,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Clear+Cell+Renal+Cell+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Clear+Cell+Renal+Cell+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T00:39:15.879Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04436120",
      "title": "Treatment Resistance Following Anti-cancer Therapies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Disease Progression"
      ],
      "interventions": [
        {
          "name": "De novo tumor tissue biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Research blood draws",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-02-13",
      "completion_date": "2020-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 17,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04436120"
    },
    {
      "nct_id": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer",
        "Other Solid Tumors",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Mantle Cell Lymphoma",
        "Indolent B-cell Lymphomas",
        "Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Waldenstrom's Disease",
        "Marginal Zone Lymphoma",
        "Mucosa Associated Lymphoid Tissue",
        "Small Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CDX-1140",
          "type": "DRUG"
        },
        {
          "name": "CDX-301",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2017-12-01",
      "completion_date": "2022-09-13",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329950"
    },
    {
      "nct_id": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors With HRAS Alterations",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Colorectal Cancer (CRC)",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Clear Cell Renal Cell Carcinoma (ccRCC)",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Non Clear Cell Renal Cell Carcinoma (nccRCC)"
      ],
      "interventions": [
        {
          "name": "Darlifarnib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-10-18",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026410"
    },
    {
      "nct_id": "NCT07555210",
      "title": "Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer (Triple Negative Breast Cancer (TNBC))",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Melanoma (Skin Cancer)",
        "Non-Small Cell Lung Cancer",
        "MSI-H/dMMR Rectal Cancer",
        "Squamous Cell Carcinoma Mouth",
        "Invasive Mammary Carcinoma",
        "Classic Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Dual-Energy X-ray Absorptiometry (DXA)",
          "type": "DEVICE"
        },
        {
          "name": "High Resolution peripheral Quantitative Computed Tomography (HRpQCT)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Jessica Mezzanotte Sharpe",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2025-08-25",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07555210"
    },
    {
      "nct_id": "NCT07160335",
      "title": "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HLX17",
          "type": "DRUG"
        },
        {
          "name": "US-sourced Keytruda®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 174,
      "start_date": "2025-09-26",
      "completion_date": "2028-03-27",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 12,
      "location_summary": "Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07160335"
    },
    {
      "nct_id": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Kidney Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Renal Cell Cancer AJCC v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nelfinavir Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-06-09",
      "completion_date": "2020-07-12",
      "has_results": true,
      "last_update_posted_date": "2022-06-22",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050060"
    },
    {
      "nct_id": "NCT05059444",
      "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Carcinoma",
        "Ureter Carcinoma",
        "Renal Pelvis Carcinoma",
        "Non-small Cell Lung Cancer",
        "Invasive Breast Carcinoma",
        "Cutaneous Melanoma",
        "Esophageal Carcinoma",
        "Gastroesophageal Junction Carcinoma",
        "Gastric Adenocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Epithelial Ovarian Carcinoma",
        "Fallopian Tube Carcinoma",
        "Endometrial Carcinoma",
        "Renal Cell Carcinoma",
        "Rectal Adenocarcinoma",
        "Colon Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Guardant Reveal",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Guardant Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2285,
      "start_date": "2021-09-07",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05059444"
    },
    {
      "nct_id": "NCT04831138",
      "title": "Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "MRI with ASL",
          "type": "OTHER"
        },
        {
          "name": "ASL-MRI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-03-24",
      "completion_date": "2023-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04831138"
    },
    {
      "nct_id": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Resectable Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "INBRX-106 - Hexavalent OX40 agonist antibody",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 200 mg",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-5",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC-6",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed 500 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin 75mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel 100mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (1000 mg/m2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inhibrx Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2019-12-10",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04198766"
    },
    {
      "nct_id": "NCT00005851",
      "title": "Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Renal Cell Cancer",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "Up to 74 Years"
      },
      "enrollment_count": 11,
      "start_date": "2000-02",
      "completion_date": "2018-09-27",
      "has_results": false,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-10-12T00:39:15.879Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005851"
    }
  ]
}